As a general principle, any research involving humans requires voluntary participation based on informed consent.^[@R1]^ This also applies to enrollment in clinical trials und usually requires participants to give written informed consent after having received detailed information about potential benefits and risks as well as alternative treatment options, and after having had adequate time for consideration. Trials in acute stroke, however, present several challenges to this approach. Reperfusion therapies in acute stroke show a clear time-dependent effect, being more effective the earlier treatment is started, or reperfusion achieved.^[@R2],[@R3]^ Both routine care and clinical trials in acute stroke are carried out under pressure of time. Thus, time available for consideration is very short. In addition, the brain injury commonly compromises language function, awareness of neurologic deficits, conscious level, and physical abilities, including vision and writing, relevant to the usual consent process. Since most stroke patients lack capacity to provide consent,^[@R4],[@R5]^ alternative approaches are needed,^[@R6],[@R7]^ and the bias introduced by systematic exclusion of certain subgroups of stroke patients, e.g., those with aphasia, has been reviewed critically.^[@R8]^

Previous stroke trials point towards possible meaningful differences between patients able to give consent by themselves and those enrolled by proxy consent, with patients enrolled by proxy consent being more severely affected.^[@R9],[@R10]^ However, the number of studies addressing this research question is small, and it is uncertain how the manner of obtaining consent affects further characteristics of stroke patients enrolled in clinical trials and how this might affect the generalizability of trial results. To address this question, we analyzed data of the first 1,005 patients enrolled in WAKE-UP, a European multicenter randomized controlled clinical trial of IV thrombolysis in acute stroke patients with unknown time of symptom onset based on MRI.^[@R11]^ We study the effect of the manner of consent on the clinical characteristics of patients enrolled. Moreover, we also describe national variations in the manner of obtaining informed consent, an issue that has not yet been studied for acute stroke trials.

METHODS {#s1}
=======

Study population. {#s1-1}
-----------------

WAKE-UP (Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial) is an investigator-initiated, randomized, double-blind, placebo-controlled trial designed to test the efficacy and safety of IV thrombolysis in patients with unknown time of symptom onset selected by MRI.^[@R11]^ Patients are screened with MRI including diffusion-weighted imaging (DWI) and fluid-attenuated inversion recovery (FLAIR), and the presence of a DWI--FLAIR mismatch indicating ischemic stroke lesion \<4.5 hours^[@R12]^ represents the main imaging criterion for randomization to treatment with either IV tissue plasminogen activator or placebo. The trial was started in September 2012. The present analysis includes baseline data of patients enrolled until April 1, 2016. Only information recorded at baseline was analyzed, and only data of patients with at least information concerning informed consent, symptom onset, age, and sex were included.

Standard protocol approvals, registrations, and patient consents. {#s1-2}
-----------------------------------------------------------------

WAKE-UP was approved by the national competent authorities and ethics committees in all participating countries. WAKE-UP was registered at [clinicaltrials.gov](http://www.clinicaltrials.gov/) (NCT01525290) and [clinicaltrialsregister.eu](https://www.clinicaltrialsregister.eu/) (2011-005906-32).

Informed consent has to be obtained prior to enrollment of patients in the trial. Options for proxy consent are given in accordance with the following European and national regulations ([figure 1](#F1){ref-type="fig"}):

![Approaches to informed consent in WAKE-UP\
The different means of obtaining informed consent in WAKE-UP depending on the ability of the patient to give informed consent and on the availability of a legal guardian. The means of informed consent allowed for patient enrollment differed by country according to national regulations and the approval of national and regional ethics committees.](NEUROLOGY2016791053FF1){#F1}

A: The patient is judged to have capacity to give informed consent and able to provide written consent: the patient provides written consent.

B: The patient is judged to have capacity to give informed consent but unable to provide written consent due to a physical barrier: the patient provides witnessed oral consent and provides later written consent as soon as possible.

C: The patient lacks capacity to give informed consent, legal guardian is available: the legal guardian acts on behalf of the patient and provides written consent.

D: The patient lacks capacity to give informed consent, legal guardian is not available, informed consent by next of kin: next acts on behalf of the patient following the patient\'s presumed will and provides written consent; patient or legal guardian provides later written consent as soon as possible.

E: The patient lacks capacity to give informed consent, legal guardian is not available, enrollment of patient by consensus between investigator and independent physician: the patient may be enrolled by consensus between the investigator and an independent physician; if possible, patient\'s next of kin should be contacted to appraise the patient\'s presumed will; the patient or legal guardian provides later written consent as soon as possible.

F: The patient lacks capacity to give informed consent, legal guardian is not available, enrollment of patient by investigator: the patient may be enrolled by the investigator acting on behalf of the patient following the patient\'s presumed will; if possible, the patient\'s next of kin should be contacted to appraise the patient\'s presumed will; the patient or legal guardian provides later written consent as soon as possible.

Clinical examinations and MRI at baseline. {#s1-3}
------------------------------------------

Neurologic examination was performed by certified investigators using the NIH Stroke Scale (NIHSS).^[@R13]^ Information on time of symptom recognition and of the time point last seen well was obtained from patients or caregivers, and the reason why exact symptom onset was unknown was recorded according to 5 categories: night sleep, day sleep, unwitnessed stroke with aphasia, unwitnessed stroke with confusion, other. Time of admission to hospital was obtained from the medical records.

MRI including DWI and FLAIR was performed according to the trial protocol. Local investigators judged DWI--FLAIR mismatch according to standards provided together with the study protocol and after completion of a computer-based image judgement training and certification. Presence of a visible acute ischemic lesion on DWI, DWI--FLAIR mismatch, and any signs of intracranial haemorrhage were recorded.

Statistical analysis. {#s1-4}
---------------------

Demographic and clinical characteristics as well as imaging findings at baseline are described and compared between groups. The following delays were calculated: time between last seen well and symptom recognition, time between symptom recognition and hospital admission, time between hospital admission and informed consent, and time between hospital admission and administration of the study drug. In addition to the NIHSS sum score, presence of aphasia as assessed by item 9 of the NIHSS and disturbance of level of consciousness as assessed by item 1a of the NIHSS were analyzed separately as categorical variables.

Descriptive statistics are provided including median (interquartile range \[IQR\]) and percentages for continuous and categorical data, respectively. For group comparison, the manner of informed consent was dichotomized into informed consent by the patient personally (written or oral: A, B) or informed consent by proxy (legal guardian, next of kin, consultant, or investigator: C, D, E, F). The manner of obtaining informed consent was also compared among countries for the 6 countries enrolling patients at the time of database export (Belgium, Denmark, France, Germany, Spain, United Kingdom). Fisher exact test or χ^2^ test was used to compare groups for categorical variables, and the Kruskal-Wallis test was used for continuous variables. In order to account for heterogeneity among countries, group comparisons were repeated by fitting a logistic regression model of the odds of informed consent given by proxy according to each factor adjusted for country. All analyses are considered exploratory. SAS software, version 9.3 (SAS Institute Inc., Cary, NC) was used for all analyses.

RESULTS {#s2}
=======

Of 1,039 patients enrolled in the trial, 1,005 patients met the inclusion criteria and were included in the analysis. Median age was 68 years (IQR 58--75 years); 38.8% of patients were women. In 646 (64.3%) patients, informed consent was given by the patients themselves, while in 359 (35.7%), informed consent was by proxy (see [table 1](#T1){ref-type="table"} for distribution of means of informed consent).

###### 

Means of informed consent used for enrollment

![](NEUROLOGY2016791053TT1)

Patients enrolled via informed consent by proxy were older (median 71 vs 66 years, *p* \< 0.0001) and were more frequently female (49.9% vs 32.7%, *p* \< 0.0001; [table 2](#T2){ref-type="table"}). They also had a longer delay between the time point last seen normal and the time of symptom recognition (8.9 vs 7.3 hours, *p* \< 0.0001). In contrast, the delay between symptom recognition and hospital arrival was shorter (1.5 vs 1 hour, *p* \< 0.0001). Regarding trial-related activities, the delays between hospital admission and informed consent and between admission to hospital and the start of study drug, respectively, were longer for patients with informed consent by proxy, but in the additional analysis adjusted for country, no significant association was found.

###### 

Clinical characteristics by means of informed consent

![](NEUROLOGY2016791053TT2)

Arterial hypertension was observed more frequently in patients with informed consent by proxy (58.2% vs 43.4%, *p* = 0.0022). Diabetes mellitus, hypercholesterolemia, and atrial fibrillation also were observed more frequently in patients with proxy consent, but the difference was not significant after adjustment for country. Patients enrolled via informed consent by proxy presented with a more severe neurologic deficit on admission, reflected by higher values on the NIHSS (median 11 vs 5, *p* \< 0.0001). They also showed more frequently aphasia (73.7% vs 20.0%, *p* \< 0.0001) and disturbed level of consciousness (17.0% vs 3.4%, *p* \< 0.0001). Of note, MRI findings (i.e., findings of intracranial haemorrhage, acute DWI lesions, and DWI--FLAIR mismatch) did not differ between groups.

The relative frequency of the manner of informed consent used for enrollment varied among countries (*p* \< 0.001; [table 1](#T1){ref-type="table"}). Written consent by patients themselves was the most frequent manner of informed consent in all countries apart from Spain (ranging from 86.0% in Denmark to 19.6% in Spain). Informed consent by next of kin ranged from 67.4% in Spain to not being used at all in Denmark. Enrollment by independent physician was used in 21.2% of cases in Germany but was only rarely used in other countries. In contrast, enrollment by investigator was common in France (35.5%), less frequent in Belgium (8.2%), but only used in single cases in the other countries. Overall, the proportion of informed consent by proxy ranged from 77.1% in Spain to 1.2% in Denmark ([figure 2](#F2){ref-type="fig"}).

![Manner of obtaining informed consent by country\
The distribution of the different means of informed consent obtained in WAKE-UP, i.e., either by patients themselves or by proxy, for the 6 countries participating in the trial at the time of database extraction for the current analysis.](NEUROLOGY2016791053FF2){#F2}

DISCUSSION {#s3}
==========

In this analysis of baseline data of the first 1,005 patients enrolled in the WAKE-UP trial, about 1 in 3 patients were enrolled by proxy consent. In these cases, consent was provided by the legal guardian, by next of kin, by an independent consultant, or by the investigator based on an emergency clause. There were marked differences in clinical characteristics between patients depending on how informed consent was obtained. Patients enrolled by proxy consent were older, more frequently hypertensive, and had more severe stroke symptoms reflected by higher NIHSS scores. Patients enrolled by proxy consent were also about 3.5 times more likely to be aphasic and 5 times more likely to have a disturbed level of consciousness. These observations are consistent with previous observations.^[@R4],[@R8]^ Both prestroke conditions (i.e., higher age, more severe comorbidity) and stroke-related factors (i.e., more severe neurologic symptoms including higher rate of aphasia) contribute to lack of capacity to give informed consent.

Our findings are consistent with observations from 2 other trials of IV thrombolysis. In the National Institute of Neurological Disorders and Stroke trial, 439 of 624 (70%) patients were enrolled by proxy consent, and these patients were older and more severely affected.^[@R9]^ In the first 300 patients enrolled in the third International Stroke Trial (IST-3), patients with nonlacunar hemispheric stroke syndromes and those with a more severe neurologic deficit were more likely to have been enrolled by proxy consent.^[@R10]^ Observations of imaging characteristics have noted smaller DWI volumes and absence of large artery occlusion among patients without capacity to consent.^[@R14]^ These results underline that restricting enrollment to patients with capacity for consent will systematically exclude specific subgroups of stroke patients and result in populations that are not representative of acute stroke patients in general.^[@R15]^ In a Cochrane review on information provision to stroke patients and caregivers, only 10 of 14 randomized controlled trials included in the review excluded patients with aphasia due to incapacity to consent.^[@R16]^ In a single-center interventional stroke trial, inability to consent applied as exclusion criterion to 330 of 1,194 (28%) patients.^[@R17]^ The effects of such restrictions include systematic exclusion of patients with some types of neurologic deficit (e.g., aphasia) from acute stroke research,^[@R8]^ loss of generalizability, and slower recruitment rates. Many imaging endpoint biomarkers are likely to be uninformative with such restrictions.

We focused on a comparison of clinical data between patients capable of consent and those not capable without further detailed comparison of the subgroups of patients enrolled with different approaches to proxy consent. However, from an ethics perspective, there is a fundamental difference between surrogate consent (category C/D), considered to represent meaningful patient-centered consent, and physician consent in the absence of direct or surrogate consent (category E/F). We performed additional analyses subdividing the group of patients enrolled by proxy consent into patient-centered surrogate consent (C/D) and physician consent (E/F). This comparison revealed only slight differences in presenting symptoms, with disturbed level of consciousness and aphasia being slightly more frequent for physician consent (20.4% and 79.6%) as compared to patient-centered surrogate consent (14.9% and 70.1%), while age, sex distribution, and median NIHSS were comparable for the 2 subgroups of proxy consent.

Informed consent is considered a fundamental ethical principle of any research involving humans as described in the Declaration of Helsinki.^[@R1]^ However, the Declaration of Helsinki also recognizes the problem of obtaining informed consent from patients in critical conditions and suggests different approaches to informed consent. The Food and Drug Administration as well as competent authorities in most European countries allow emergency research without informed consent under strictly defined circumstances. Only limited guidance is provided on how to regulate clinical research in patients incapable of giving informed consent, and as a consequence very different approaches for obtaining informed consent are used in different stroke trials and, within trials, among countries or trial sites.^[@R18]^

At the time of database extraction for the current analysis, WAKE-UP was running in 6 European countries: Belgium, Denmark, France, Germany, Spain, and the United Kingdom. In principle, the EU directive on clinical trials (EC) No. 2001/20/EC^[@R19]^ applies to all of these countries, providing rules for trials in emergency situations. However, the regulations provided in the directive are ambiguous and require interpretation. As a consequence, national regulations and interpretation of these regulations by institutional review boards and ethics committees are implemented with heterogeneous results, leading to a great diversity of national practice with regards to enrollment of incapable patients in Europe.^[@R20]^ Within the WAKE-UP trial, we assured that multiple options for informed consent were available. The use of the 5 available approaches differed among the 6 countries. Of note, the proportion of proxy consent varied largely among countries, being hardly used at all in Denmark (1.2%) but in more than 2-thirds of patients in Spain (77.1%). Differences in approval of informed consent for the trial between countries may partly explain this variation (i.e., no approval for proxy consent beyond consent by a legal guardian in Denmark, no approval for consent by investigator in Germany and the United Kingdom). With regards to further reasons for the observed variation, we may only speculate. Differences in the attitude towards and in experience with different manners of informed consent among countries may also play a role. Independent from underlying reasons, these findings may inform the conduct of multinational stroke trials in the future as well as in other disease areas where proxy consent is likely to be used.

Country effects in clinical trials are generally assumed to be largely due to chance and small patient numbers in the individual countries.^[@R21]^ However, there may be effects that reflect differences in populations or the clinical setting among countries, resulting in differences in patient characteristics or arguably treatment effect. We observed a confounding effect of country on the association between the manner of informed consent and clinical characteristics that appears plausible in reflecting country-specific aspects of the trial setting. The observed shorter time delay between hospital admission and treatment initiation in patients providing informed consent themselves appeared to be largely driven by a shorter mean delay between hospital admission and treatment initiation in Denmark as compared to all other countries, together with the fact that in Denmark virtually all patients were enrolled based on self-consent. These observations have to be interpreted with caution, as we cannot rule out potential center-level effects. However, given this limitation, our observations suggest that the choice of countries in which a trial should be run may modify the characteristics of the study population and hence may also influence the effects of the treatment under investigation.

There are statistical approaches to managing site differences in clinical trials, which broadly enclose the options of ignoring possible site effects, or of modeling them as either fixed effects or random effects.^[@R22]^ There is, however, no standard solution for this problem, but the best strategy for controlling site effects depends on the expected effects, including confounding and site-by-treatment interaction. In WAKE-UP, randomization is stratified by site in order to avoid imbalances between sites concerning treatment allocation, and site and country will be addressed as confounding factors in the final statistical analysis.

The time-critical nature of interventions, the high prevalence of incapacity in acute stroke, and the demonstrable effect of proxy consent on trial conduct and populations call for considering approaches that might expedite proxy consent procedures for stroke clinical research, as has been considered in other emergency conditions.^[@R23],[@R24]^ The Council for International Organizations of Medical Sciences has recently proposed new international ethical guidelines for health-related research involving humans that, among other issues, address research in emergency settings and in patients incapable of providing informed consent.^[@R25]^ There is an urgent need for clearer, more homogeneous, and more pragmatic regulations for enrollment of incapable patients into clinical trials. The opinions of stroke patients and caregivers should also be considered. In prospective interview studies, a majority of patients agreed to participate in acute stroke trials without conventional informed consent.^[@R26],[@R27]^ The concept of exception from informed consent for clinical research in neurologic emergency conditions like stroke was also generally accepted and deemed appropriate given approval of institutional review boards in a qualitative study of several focus groups including stroke patients, their families, and healthy young individuals.^[@R28]^

In a large population of patients enrolled in a randomized controlled trial of IV thrombolysis in stroke, we demonstrate that the manner of informed consent affects the clinical characteristics of patients. In addition, the manner of informed consent differed significantly among countries. These findings illustrate the importance of identifying strategies for the inclusion of incapable patients in acute stroke trials. As of yet, reperfusion treatment is the only effective treatment strategy for acute stroke, and it is still only available for a limited subgroup of stroke patients. Further clinical trials improving treatment of acute stroke and testing new treatment approaches are urgently needed. Currently, differences in national regulations and diverging practice to informed consent may hamper trial success. More harmonized interpretation and implementation of international regulations into national practice is required to enable comparable practice including all different manners of consent in an emergency setting among different countries.
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